Movatterモバイル変換

[0]ホーム

Jump to content

TRV734

Add links

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

TRV734
Identifiers

IUPAC name N-[(5-fluoropyridin-3-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine
CAS Number	1401029-50-2^Y
PubChemCID	72695064
Chemical and physical data
Formula	C₂₂H₂₈FN₃O
Molar mass	369.484 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1CCC2(C1)C[C@](CCO2)(CCNCC3=CC(=CN=C3)F)C4=CC=CC=N4
InChI InChI=1S/C22H28FN3O/c23-19-13-18(15-25-16-19)14-24-11-8-21(20-5-1-4-10-26-20)9-12-27-22(17-21)6-2-3-7-22/h1,4-5,10,13,15-16,24H,2-3,6-9,11-12,14,17H2/t21-/m1/s1 Key:CRKVMJHROLSFMV-OAQYLSRUSA-N

TRV734 is a drug developed byTrevena Inc which acts as a biased agonist at theμ-opioid receptor, selective for activation of theG-protein signalling pathway overβ-arrestin 2 recruitment. It is closely related tooliceridine and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.^[1]

References

[edit]

^James IE, Skobieranda F, Soergel DG, Ramos KA, Ruff D, Fossler MJ (February 2020). "A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor".Clinical Pharmacology in Drug Development.9 (2):256–266.doi:10.1002/cpdd.721.PMID 31286645.S2CID 195843184.